Challenges translating breast cancer gene signatures into the clinic
- PMID: 21878891
- DOI: 10.1038/nrclinonc.2011.125
Challenges translating breast cancer gene signatures into the clinic
Abstract
The advent of microarray-based gene-expression profiling a decade ago raised high expectations for rapid advances in breast cancer classification, prognostication and prediction. Despite the development of molecular classifications, and prognostic and predictive gene-expression signatures, microarray-based studies have not yielded definitive answers to many of the questions that remain germane for the successful implementation of personalized medicine. There are a lack of robust signatures to predict benefit from specific therapeutic agents and it is still not possible to predict prognosis or chemotherapy treatment response in specific disease subsets accurately, such as triple-negative breast cancer. We discuss the hurdles in the development and validation of molecular classification systems, and prognostic and predictive signatures based on microarray gene-expression profiling. We suggest that similar challenges are likely to be encountered in translating next-generation sequencing data into clinically useful information. Finally we highlight strategies for the development of clinically useful molecular predictors in the future.
Similar articles
-
Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.BMC Cancer. 2015 Mar 26;15:179. doi: 10.1186/s12885-015-1102-7. BMC Cancer. 2015. PMID: 25886164 Free PMC article.
-
Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.Breast Cancer Res. 2011 Jun 27;13(3):212. doi: 10.1186/bcr2890. Breast Cancer Res. 2011. PMID: 21787441 Free PMC article. Review.
-
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.Breast Cancer Res. 2010;12(5):R85. doi: 10.1186/bcr2753. Epub 2010 Oct 14. Breast Cancer Res. 2010. PMID: 20946665 Free PMC article.
-
Multigene prognostic tests in breast cancer: past, present, future.Breast Cancer Res. 2015 Jan 27;17(1):11. doi: 10.1186/s13058-015-0514-2. Breast Cancer Res. 2015. PMID: 25848861 Free PMC article. Review.
-
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.PLoS One. 2011;6(12):e28403. doi: 10.1371/journal.pone.0028403. Epub 2011 Dec 29. PLoS One. 2011. PMID: 22220191 Free PMC article.
Cited by
-
The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.PLoS One. 2015 Jul 1;10(7):e0129711. doi: 10.1371/journal.pone.0129711. eCollection 2015. PLoS One. 2015. PMID: 26132585 Free PMC article.
-
Circulating tumour cells and cell-free DNA as tools for managing breast cancer.Nat Rev Clin Oncol. 2013 Jul;10(7):377-89. doi: 10.1038/nrclinonc.2013.80. Epub 2013 May 28. Nat Rev Clin Oncol. 2013. PMID: 23712187 Review.
-
Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study.Breast Cancer Res. 2017 Oct 13;19(1):113. doi: 10.1186/s13058-017-0881-y. Breast Cancer Res. 2017. PMID: 29029636 Free PMC article.
-
MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.Oncogene. 2016 Jan 28;35(4):448-58. doi: 10.1038/onc.2015.96. Epub 2015 Apr 13. Oncogene. 2016. PMID: 25867061 Free PMC article. Clinical Trial.
-
Differential proteomic analysis of pathway biomarkers in human breast cancer by integrated bioinformatics.Oncol Lett. 2012 Nov;4(5):1097-1103. doi: 10.3892/ol.2012.881. Epub 2012 Aug 24. Oncol Lett. 2012. PMID: 23162659 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical